L1 Capital Global Opportunities Master Fund, Ltd. 13D and 13G filings for Titan Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-11 5:48 pm Sale | 2021-12-31 | 13G | Titan Pharmaceuticals, Inc. TTNP | L1 Capital Global Opportunities Master Fund, Ltd. | 24,736 4.990% | -9,327 (-27.38%) | Filing |
| 2021-01-25 08:26 am Purchase | 2021-01-15 | 13G | Titan Pharmaceuticals, Inc. TTNP | L1 Capital Global Opportunities Master Fund, Ltd. | 34,063 6.900% | 17,863 (+110.26%) | Filing |
| 2020-10-01 4:41 pm Purchase | 2020-09-24 | 13G | Titan Pharmaceuticals, Inc. TTNP | L1 Capital Global Opportunities Master Fund, Ltd. | 16,200 8.300% | 16,200 (New Position) | Filing |